Remus Pharmaceuticals Complete Financial Statements
In FYNone, Remus Pharmaceuticals (REMUS) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹0.00, with a net profit margin of 5.4% and ROE of 13.1%. Full financial statements from FY2024 to FY2026 (3 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Analyse Remus Pharmaceuticals ownership pattern to track promoter, FII and institutional holdings.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
REMUS Revenue, Net Profit & EBITDA — Year-on-Year Growth
REMUS YoY (March 2026 vs Period) — revenue -100.0%, net profit -100.0%, EBITDA -100.0%, expenses -100.0%. Also explore REMUS price trends to track price trends across different timeframes.
REMUS Income Statement — Revenue, EBITDA & Net Profit
Remus Pharmaceuticals revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (None) — net profit margin 5.4%. For live price, earnings ratios and company overview, see REMUS share price.
| Particulars | None | March 2026 | March 2025 | March 2024 |
|---|---|---|---|---|
| Revenue | 0 | 854 | 625 | 218 |
| Expenses | 0 | 797 | 575 | 185 |
| EBITDA | 0 | 57 | 51 | 33 |
| Operating Profit Margin % | 0.00% | 7.00% | 7.00% | 13.00% |
| Depreciation | 0 | 3 | 2 | 1 |
| Interest | 0 | 1 | 2 | 1 |
| Profit Before Tax | 0 | 59 | 47 | 32 |
| Tax | 0 | 13 | 9 | 6 |
| Net Profit | 0 | 46 | 38 | 26 |
| Earnings Per Share (₹) | 0.00 | 39.19 | 65.21 | 152.01 |
REMUS Balance Sheet — Assets, Liabilities & Shareholders' Equity
REMUS total assets ₹579 Cr, total equity ₹351 Cr, total liabilities ₹ Cr (2026) — ROE 13.1%.
| Particulars | 2026 | 2025 | 2024 |
|---|---|---|---|
| ASSETS | |||
| Total Assets | 579 | 433 | 257 |
| Current Assets | 295 | 221 | 210 |
| Fixed Assets | 18 | 16 | 12 |
| Capital Work in Progress | 8 | 0 | 0 |
| Investments | 72 | 186 | 4 |
| Other Assets | 0 | 231 | 242 |
| LIABILITIES | |||
| Total Liabilities | |||
| Current Liabilities | 42 | 29 | 4 |
| Non-Current Liabilities | |||
| SHAREHOLDERS' EQUITY | |||
| Total Equity | 351 | 283 | 104 |
| Share Capital | 12 | 6 | 2 |
| Reserves & Surplus | 339 | 250 | 85 |
REMUS Cash Flow Statement — Operating, Investing & Financing
Remus Pharmaceuticals operating cash flow ₹7 Cr, investing ₹-11 Cr, financing ₹6 Cr, net cash flow ₹3 Cr (2025).
| Particulars | March 2025 | March 2024 |
|---|---|---|
| Operating Activities | 7 | 4 |
| Investing Activities | -11 | -9 |
| Financing Activities | 6 | 24 |
| Net Cash Flow | 3 | 19 |